Peptipedia
BioregulatorNot FDA ApprovedClinical Trials

Pancragen

Also known as KEDW Tetrapeptide, Lys-Glu-Asp-Trp

Synthetic tetrapeptide bioregulator originally isolated from bovine pancreatic cells, developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology.

Approved in Russia - Clinical use for pancreatic support
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

1-2 capsules (10-20 mg) daily

Frequency

1-2x daily, before meals

Duration

30-day courses with 3-6 month breaks

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 1-2 capsules (10-20 mg) daily via Oral capsules, before meals, 1-2x daily, before meals. Dose range: 10-20 mg daily. Duration: 30-day courses with 3-6 month breaks.

Timing & Administration

Administer via Oral capsules, before meals. Frequency: 1-2x daily, before meals.

Mechanism of Action

Works through epigenetic regulation by interacting with chromatin complexes and DNA structures. Upregulates transcription factors including Pdx1, Pax6, Ptf1a, Foxa2, Nkx2.2, and Pax4.

Research Summary

Evidence level: clinical trials. Clinical status: Approved in Russia - Clinical use for pancreatic support.

Side Effects & Safety

Important Warnings

  • Should not replace diabetes medications
Generally well-tolerated
no significant adverse effects reported
individual intolerance possible

References

No references available.

Related Peptides

Browse all →
BPC-157Healing

A synthetic peptide derived from a protein found in human gastric juice. Extensive preclinical studies demonstrate efficacy in healing tendons, ligaments, muscles, and the GI tract.

View profile
TB-500Healing

A synthetic 17-amino acid fragment of Thymosin Beta-4 with a longer half-life (~2-4 days) compared to the full protein (~2 hours).

View profile
SemaglutideWeight Loss

A GLP-1 receptor agonist with multiple FDA approvals including weight management, type 2 diabetes treatment, cardiovascular risk reduction, and kidney disease protection. 94% amino acid similarity to human GLP-1.

View profile